Compare CPBI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPBI | TENX |
|---|---|---|
| Founded | 2023 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 71.1M |
| IPO Year | 2023 | 2001 |
| Metric | CPBI | TENX |
|---|---|---|
| Price | $21.00 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 1.6K | ★ 8.3M |
| Earning Date | 06-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.38 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.56 | $1.31 |
| 52 Week High | $21.83 | $19.40 |
| Indicator | CPBI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 66.26 | 22.44 |
| Support Level | $16.88 | $1.31 |
| Resistance Level | $21.83 | $16.39 |
| Average True Range (ATR) | 0.15 | 0.32 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 95.06 | 6.57 |
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.